Granted Patent
B2
US 12,686,724 · App. 17/917,513 · Granted Jul 21, 2026
Monoclonal antibodies and antigen binding fragments thereof for suppressing CD73 immune checkpoint and uses thereof
Assignee:
Aprilbio Co., Ltd
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Provided are monoclonal antibodies and antigen binding fragments thereof for suppressing a CD73 immune checkpoint, and uses thereof, wherein the antibodies or antigen binding fragments thereof can bind to CD73, reduce enzymatic activity of CD73 protein, and inhibit cancer metastasis or cancer growth, thus enabling uses thereof as therapeutic agents for cancer.
Claims (12)
1 . A monoclonal antibody or an antigen binding fragment thereof comprising:
a heavy chain variable region comprising a heavy chain complementarity determining domain 1 (CDRH1) comprising the amino acid sequence of SEQ ID NO: 78, CDRH2 comprising the amino acid sequence of SEQ ID NO:79, and CDRH3 comprising the amino acid sequence of SEQ ID NO:80; and
a light chain variable region comprising CDRL1 comprising the amino acid sequence of SEQ ID NO:93, CDRL2 comprising the amino acid sequence of SEQ ID NO:94, and CDRL3 comprising the amino acid sequence of SEQ ID NO:95.
2 . The antibody or the antigen binding fragment thereof of claim 1 , wherein the antibody is a human antibody or chimeric antibody.
3 . A nucleic acid encoding the antibody or the antigen binding fragment thereof of claim 1 .
4 . An expression vector comprising the nucleic acid of claim 3 .
5 . A cell transformed with the expression vector of claim 4 .
6 . A composition comprising the antibody or the antigen binding fragment thereof of claim 1 .
7 . The composition of claim 6 , further comprising an immune checkpoint blockade or a chemotherapeutic agent.
8 . A method of treating cancer in a subject in need thereof, comprising administering the antibody or antigen binding fragment thereof of claim 1 to the subject, wherein the cancer is a CD73 overexpressing cancer.
9 . The method of claim 8 , wherein the cancer is breast cancer, triple-negative breast cancer (TBNC), pancreatic colorectal cancer, ovarian cancer, gastric cancer, bladder cancer, leukemia, prostate cancer, malignant melanoma, cancer, esophageal cancer, stomach cancer, head and neck cancer, lung cancer, or kidney cancer.
10 . The antibody or the antigen binding fragment thereof of claim 1 , comprising: a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:104; and a light chain variable region comprising the amino acid sequence of SEQ ID NO:105.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Oct 6, 2022
From: CHA, SANG HOON
To: APRILBIO CO., LTD.
Reel/Frame 061340/0818 →
Priority Claims (2)
KR 10-2020-0043607
· Apr 9, 2020
· national
KR 10-2020-0144595
· Nov 2, 2020
· national
Continuity (1)
Related Publication
20230174665A1
· Jun 8, 2023
References Cited (161)
US 6610515B1
· Yamamoto et al.
· 2003
[cited by applicant]
US 7439336B2
· Kornmann et al.
· 2008
[cited by applicant]
US 7691611B2
· Weber et al.
· 2010
[cited by applicant]
US 7820800B2
· Rossi et al.
· 2010
[cited by applicant]
US 7943746B2
· Kornmann et al.
· 2011
[cited by applicant]
US 8128920B2
· Sagot et al.
· 2012
[cited by applicant]
US 8217152B2
· Le Strat et al.
· 2012
[cited by applicant]
US 8846042B2
· Zhou
· 2014
[cited by applicant]
US 8921528B2
· Holt et al.
· 2014
[cited by applicant]
US 9566313B2
· Chvatchko et al.
· 2017
[cited by applicant]
US 9592267B2
· Chvatchko et al.
· 2017
[cited by applicant]
US 9879077B2
· Cha
· 2018
[cited by applicant]
US 20040229338A1
· King
· 2004
[cited by applicant]
US 20060269515A1
· Denis-Mize et al.
· 2006
[cited by applicant]
US 20070059301A1
· Humphreys et al.
· 2007
[cited by applicant]
US 20090111745A1
· Tomlinson
· 2009
[cited by applicant]
US 20100227818A1
· Bock et al.
· 2010
[cited by applicant]
US 20110177065A1
· Rubinstein et al.
· 2011
[cited by applicant]
US 20140044675A1
· Hosse et al.
· 2014
[cited by applicant]
US 20220242963A1
· Griffin
· 2022
[cited by examiner]
CN 101280019A
· 2008
[cited by applicant]
CN 107082815A
· 2017
[cited by applicant]
EP 1033373A1
· 2000
[cited by applicant]
EP 3297672A1
· 2018
[cited by applicant]
EP 3569618A1
· 2019
[cited by applicant]
JP H04502164A
· 1992
[cited by applicant]
JP H11196881A
· 1999
[cited by applicant]
JP 2007535472A
· 2007
[cited by applicant]
JP 2008500830A
· 2008
[cited by applicant]
JP 2018501197A
· 2018
[cited by applicant]
KR 20070041781A
· 2007
[cited by applicant]
KR 20070073886A
· 2007
[cited by applicant]
KR 20110008086A
· 2011
[cited by applicant]
KR 20120133403A
· 2012
[cited by applicant]
KR 1020150118565A
· 2015
[cited by applicant]
KR 1020190080992A
· 2019
[cited by applicant]
WO 1987000532A1
· 1986
[cited by applicant]
WO 9105798A1
· 1991
[cited by applicant]
WO 1999009063A1
· 1999
[cited by applicant]
WO 9920652A1
· 1999
[cited by applicant]
WO 0187330A2
· 2001
[cited by applicant]
WO 2004101617A1
· 2004
[cited by applicant]
WO 2005049649A1
· 2005
[cited by applicant]
WO 2005097998A2
· 2005
[cited by applicant]
WO 2005118642A2
· 2005
[cited by applicant]
WO 2006131550A1
· 2006
[cited by applicant]
WO 2008068048A2
· 2008
[cited by applicant]
WO 2010063818A2
· 2010
[cited by applicant]
WO 2010110838A2
· 2010
[cited by applicant]
WO 2011015649A1
· 2011
[cited by applicant]
WO 2012158818A2
· 2012
[cited by applicant]
WO 2013056068A1
· 2013
[cited by applicant]
WO 2015030539A1
· 2015
[cited by applicant]
WO 2015032932A1
· 2015
[cited by applicant]
WO 2016075099A1
· 2016
[cited by applicant]
WO 2016081748A2
· 2016
[cited by applicant]
WO 2016126702A1
· 2016
[cited by applicant]
WO 2016135239A1
· 2016
[cited by applicant]
WO 2016187594A1
· 2016
[cited by applicant]
WO 2017100670A1
· 2017
[cited by applicant]
WO 2017102830A1
· 2017
[cited by applicant]
WO 2017152085A1
· 2017
[cited by applicant]
WO 2017157305A1
· 2017
[cited by applicant]
WO 2018137598A1
· 2018
[cited by applicant]
WO 2018215535A1
· 2018
[cited by applicant]
WO 2018233895A1
· 2018
[cited by applicant]
WO 2018237157A1
· 2018
[cited by applicant]
WO 2019200256A1
· 2019
[cited by applicant]
WO 2019224025A2
· 2019
[cited by applicant]
WO 2021149015A1
· 2021
[cited by applicant]
WO 2021205383A1
· 2021
[cited by applicant]
WO 2021205401A1
· 2021
[cited by applicant]
WO 2022070112A1
· 2022
[cited by applicant]
WO 2022087149A1
· 2022
[cited by applicant]
WO 2022087149A2
· 2022
[cited by applicant]
WO 2024075050A1
· 2024
[cited by applicant]
WO 2024084432A1
· 2024
[cited by applicant]
WO 2025114319A1
· 2025
[cited by applicant]
WO 2025253161A1
· 2025
[cited by applicant]
Allard et al., Int. J. Cancer, 134, 1466-1473, Publication Date: Aug. 26, 2013 (Year: 2013).
[cited by examiner]
Ni et al., The Protein Journal, 43, pp. 683-696, Jul. 2024 (Year: 2024).
[cited by examiner]
International Search Report mailed Jul. 8, 2021, in International Application No. PCT/IB2021/052934.
[cited by applicant]
Written Opinion mailed Jul. 8, 2021, in International Application No. PCT/IB2021/052934.
[cited by applicant]
Extended ESR issued in the EP Application No. 21783964.6, mailed on Sep. 25, 2024.
[cited by applicant]
Miller et al., (2022) Journal of Immunotherapy of cancer, vol. 10, No. 12, Dec. 1, 2022, p. e005802, “Anti-CD73 antibody activates human B cells, enhances humoral responses and induces redistribution of B cells in patie…
[cited by applicant]
Partial ESR issued in the EP Application No. 21783964.6, mailed on Jun. 17, 2024.
[cited by applicant]
Wurm et al. (2021) Molecular Cancer Therapeutics, vol. 20, No. 11, pp. 2250-2261 “A Novel Antagonistic CD73 Antibody for Inhibition of the Immunosuppressive Adenosine Pathway”.
[cited by applicant]
Yarilin A.A., Fundamentals of Immunology: Textbook.—M.: Medicine, 608 p.; p. 171 second paragraph, pp. 172-173 (1999). Relevance in English provided in English translation of 3rd Office Action issued in RU Application N…
[cited by applicant]
Allard, B. et al., “Targeting CD73 Enhances the Antitumor Activity of Anti-PD-1 and Anti-CTLA-4 mAbs,” Intl. J. Cancer 134:1466-1473 (2013).
[cited by applicant]
Chen, X. et al., “Fusion protein linkers: Property, design and functionality,” Advanced Drug Delivery Rev. 65:1357-1369 (2013).
[cited by applicant]
Edwards, B.M. et al., “The Remarkable Flexibility of the Human Antibody Repertoire; Isolation of Over One Thousand Different Antibodies to a Single Protein, BLyS,” J. Mol. Biol. 334:103-118 (2003).
[cited by applicant]
Goel, M. et al., “Plasticity within the Antigen-Combining Site May Manifest as Molecular Mimicry in the Humoral Immune Response,” J. Immunol. 173:7358-7367 (2004).
[cited by applicant]
Janeway, Jr., C. A. et al., “Structure of the Antibody Molecule and Immunoglobulin Genes,” Immuno Biology, The Immune System in Health and Disease, 3rd ed., Current Biology Ltd. and Garland Publishing, Inc., pp. 3:1-3:1…
[cited by applicant]
Kanyavuz, A. et al., “Breaking the law: unconventional strategies for antibody diversification,” Nat. Rev. Immunol. 19:355-368 (Jun. 2019).
[cited by applicant]
Lescar, J. et al., “Crystal Structure of a Cross-reaction Complex between Fab F9.13.7 and Guinea Fowl Lysozyme,” J. Biol. Chem. 270:18067-18076 (1995).
[cited by applicant]
Lloyd, C. et al., “Modelling the human immune response: performance of a I011 human antibody repertoire against a broad panel of therapeutically relevant antigens,” Protein Engin., Design & Selection 22:159-168 (pub'd o…
[cited by applicant]
Rudikoff, S., “Single amino acid substitution altering antigen-binding specificity,” Proc. Natl. Acad. Sci. USA 79:1979-1983 (1982).
[cited by applicant]
Winkler, K. et al., “Changing the Antigen Binding Specificity by Single Point Mutations of an Anti-p24 (HIV-1) Antibody,” J. Immunol. 165(8): 4505-4514 (2000).
[cited by applicant]
Brennan et al., “Safety testing of monoclonal antibodies in in-human primates: Case studies highlighting their impact on human risk assessment,” MABS, 2018, vol. 10, No. 1, I-17.
[cited by applicant]
Chen et al., Enhancement and destruction of antibody function by somatic mutation: unequal occurrence is controlled by V gene combinatorial associations. EMBO J. Jun. 15, 1995; 14(12):2784-94. (Year: 1995).
[cited by applicant]
Cho et al., “Structural basis of serum albumin recognition by SL335, an antibody Fab extending the serum half-life of protein therapeutics,” BBRC 526:941-946, Elsevier (Mar. 2020).
[cited by applicant]
Dave, E. et al. “Fab-dsFv: A bispecific antibody format with extended serum half-life through albumin binding,” MABS vol. 8, No. 7, pp. 1319-1335 ((2016).
[cited by applicant]
European Extended Search Report issued in the EP Patent Application No. 21874697.2, mailed on Sep. 24, 2024.
[cited by applicant]
European Search Report in European Patent Application No. 14839630.2. dated Feb. 27, 2017.
[cited by applicant]
European Search Report issued in the EP Patent Application No. 21784423.2, mailed on May 13, 2024.
[cited by applicant]
European Search Report, supplemental, issued in the EP Application No. 21744981.8, mailed on Feb. 23, 2024.
[cited by applicant]
Feldon, S.E. et al., “Autologous T-Lymphocytes Stimulate Proliferation of Orbial Fibroblasts Derived from Patients with Graves' Ophthalmopathy,” Investigative Opthalmology & Visual Sci. 46:3913 (Nov. 1, 2005).
[cited by applicant]
Finkelstein A.V., Ptitsyn O.B. Physica belka: Kurs lektsiy s tsvetnymi ystereoscopitcheskimi illustratciyami i zadachami: uchebnoe posobie/A.V. Finkelstein, O.B. Ptitsyn.—4th ed., ed. And add.—M. : KDU, 2012.—524 p.: ta…
[cited by applicant]
Holt et al. “Anti-Serum Albumin Domain Antibodies for Extending the Half-Lives of Short Lived Drugs.” Protein Engineering, Design and Selection. 21(2008):283-288.
[cited by applicant]
Hong et al., “Recombinant Fc-IL-18BPc Isoform Inhibits IL-18-Induced Cytokine Production,” Hybridoma, 2012, vol. 31, pp. 99-104, Mary Ann Liebert, Larchmont, New York.
[cited by applicant]
Hust, M. et al., “Single chain Fab (scFab) fragment,” BMC Biotechnology, 7(14):1-15 (2007), BioMed Central.
[cited by applicant]
International Preliminary Report on Patentability and Written Opinion issued in the International Application No. PCT/IB2023/059986, mailed on Apr. 17, 2025.
[cited by applicant]
International Preliminary Report on Patentability and Written Opinion issued in the international application No. PCT/IB2023/060573, mailed on May 1, 2025.
[cited by applicant]
International Search Report and the Written Opinion of the International Searching Authority, or the Declaration in International Application No. PCT/IB2021/050519 mailed Apr. 23, 2021.
[cited by applicant]
International Search Report and Written Opinion in International Application No. PCT/IB2021/052934, mailed Jul. 8, 2021.
[cited by applicant]
International Search Report and Written Opinion in International Application No. PCT/IB2021/052969, mailed Jul. 16, 2021.
[cited by applicant]
International Search Report and Written Opinion in International Application No. PCT/IB2021/058964 dated Dec. 28, 2021.
[cited by applicant]
International Search Report and Written Opinion issued in International Application No. PCT/IB2023/059986, mailed on Jan. 11, 2024.
[cited by applicant]
International Search Report and Written Opinion issued in the International Application No. PCT/IB2024/055506, mailed on Feb. 25, 2025.
[cited by applicant]
International Search Report in International Patent Application No. PCT/ KR2014/008106, dated Dec. 2, 2014.
[cited by applicant]
International Search Report issued in the international application No. PCT/IB2023/060573, mailed on Feb. 2, 2024.
[cited by applicant]
International Search Report of the International Search Authority issued in the International Application No. PCT/EP2024/083686, mailed on Mar. 14, 2025.
[cited by applicant]
International Written Opinion in International Patent Application No. PCT/KR2014/008106, dated Dec. 2, 2014.
[cited by applicant]
Jazayeri et al., “Half-Life Extension by Fusion to the Fe Region.” Therapeutic Proteins. 157(2012):157-188.
[cited by applicant]
Ji et al., “Intact bioactivities and improved pharmacokinetic of the SL335-IFN-β-1a fusion protein that created by genetic fusion of SL335, a human anti-serum albumin fab, and human interferon-β”, Immunology Letters, 20…
[cited by applicant]
Jiang, Y. et al. “Effect of a structurally modified human granulocyte colony stimulating factor, G-CSFa, on leukopenia in mice and monkeys” Journal of Hematology & Oncology, Biomed Central Ltd. London UK, vol. 4, No. 1,…
[cited by applicant]
JP Office action issued in the JP Application No. 2016-538860, mailed on Mar. 21, 2017.
[cited by applicant]
Jung, S. et al., “LAPS-FSH: a new and effective long-acting follicle-stimulating hormone analogue for the treatment of infertility,” Reproduction, Fertility and Development 26:1142-1153 (2014).
[cited by applicant]
Kahaly, G.J. et al., “A Novel Anti-CD40 Monoclonal Antibody, Iscalimab, for Control of Graves Hyperthyroidism—A Proof-of-Concept Trial,” J. Clin. Endocrin. Metab. 105:696-704 (Sep. 12, 2019).
[cited by applicant]
Kanai et al., IgG1 heavy chain, partial [felis catus]—Protein—NCBI. 2020. 10. 14., GenBank: BAA32230.1, https://www.ncbi.nlm.nih.gov/protein/BAA32230.1?report=genbank&log$=protalign&blast_rank=1&RID=SD57Z4HK01R.
[cited by applicant]
Kang et al., “Isolation of Human Anti-serum albumin Fab Antibodies with an Extended Serum-half Life,” Immunology Letters 169:33-34 (Nov. 11, 2025).
[cited by applicant]
Kang, H. et al., “Optimal expression of a Fab-effector fusion protein in
[cited by applicant]
Koenig et al., “Mutational landscape of antibody variable domains reveals a switch modulating the interdomain conformational dynamics and antigen binding,” PNAS 114 (4) E486-E495, Jan. 24, 2017.
[cited by applicant]
Kussie et al., A single engineered amino acid substitution changes antibody fine specificity, J. Immuno. 152: 146-52 (1994).
[cited by applicant]
Lee, S., “Effect of long-acting recombinant human follicle stimulating hormone (SAFA-FSH) on spermatogenesis,” Master's Thesis, The Graduate School of Yonsei University, pp. 1-40, abstract and p. 13 (Dec. 2021).
[cited by applicant]
Lu et al., Ig kappa chain [Felis catus]—Protein—NCBI, 2020. 10. 14., GenBank: ATI97435.1, https://www.ncbi.nlm.nih.gov/protein/ATI97435.1?report=genbank&log$=protalign&blast_rank=1&RID=SD5885Y501R.
[cited by applicant]
Naik, V.M. et al., “Immunopathogenesis of Thyroid Eye Disease: Emerging Paradigms,” Survey of Ophthalmology, Survey of Ophthalmology Inc. 55:215-226 (May 1, 2010).
[cited by applicant]
Nicholson et al., “The enhanced immunopharmacology of VIB4920, a novel Tn3 fusion protein and CD40L antagonist, and assessment of its safety profile in cynomolgus monkeys,” British Journal of Pharmacology 177:1061-1076,…
[cited by applicant]
Nico Mertens (2011) Bispecific Antibodies, pp. 135-149“Tribodies: Fab-scFv Fusion Proteins as a Platform to Create Multifunctional Pharmaceuticals”.
[cited by applicant]
Novick et al.; (1999) “Interleukin-18 Binding Protein, A Novel Modulator of the Th1 Cytokine Response” Immun. 10:127-136.
[cited by applicant]
Qi, Y. et al., “The role of osteopontin in the induction of the CD40 ligand in Graves' disease,” Clin. Endocrin. 80:128-134, Blackwell Scientific Publications (Jun. 3, 2013).
[cited by applicant]
Second Office Action issued in the RU Application No. 2022119090/10(040313), mailed on Oct. 15, 2024.
[cited by applicant]
Sexton, L. et al., “Resistive-Pulse Studies of Proteins and Protein/Antibody Complexes Using a Conical Nanotube Sensor,” Journal of the American Chemical Society 129:13144-13152 (2007).
[cited by applicant]
Smith et al., “Prolonged in Vivo Residence Times of Antibody Fragments Associated with Albumin,” Bioconjugate Chem 12: 750-756, Apr. 12, 2001.
[cited by applicant]
Smith, D. et al, “Relevance of Half-Life in Drug Design Miniperspective,” J. Med. Chem. 61, 4273-4282 (10 pages), 2018.
[cited by applicant]
Sogaard, M. et al., “Treatment with Tumor-Reactive Fab-IL-2 and Fab-Staphylococcal Enterotoxin A Fusion Proteins Leads to Sustained T Cell Activation, and Long-Term Survival of Mice with Established Tumors,” Internation…
[cited by applicant]
Tang, A. et al., “Blockade of cD40-CD40 ligand pathway induces tolerance in muringe contact hypersensitivity,” Eur. J. Immunol. 27:3143-3150 (Jan. 1, 1997).
[cited by applicant]
Third Office Action issued in the RU Application No. 2022119090/10(040313), mailed on Mar. 14, 2025.
[cited by applicant]